MedTrace Logo

A Retrospective Real-World Cohort Study

NCT07781371 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 100000

Last updated 2026-08-24

No results posted yet for this study

Summary

The primary objectives are to determine the prevalence and overlap of major cardiometabolic diseases, identify multimorbidity clusters, and characterize demographic, clinical, laboratory, and treatment patterns across the cohort and relevant subgroups. This study is based on anonymized electronic health record (EHR) data and spanning January 2022 to December 2025. EHR will be extracted from participants of Acibadem hospital network in Turkey. Participants received routine clinical care according to physician discretion. Index date will be defined by the first diagnosis of cardiometabolic conditions.

Follow-up period will include at least one year of to allow description of long-term outcomes. It will extend until the end of study, last recorded encounter, or death.

Conditions

  • Obesity
  • Type 2 Diabetes (T2D)
  • Prediabetes
  • Cardiovascular Disease (CVD)
  • Dyslipidemia
  • Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD)
  • Chronic Kidney Disease (CKD)

Interventions

OTHER

No treatment given

No treatment given

Sponsors & Collaborators

Principal Investigators

  • Clinical Transparency (dept. 2834) · Novo Nordisk A/S

Eligibility

Min Age
12 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-08-20
Primary Completion
2026-11-02
Completion
2026-11-02

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07781371 on ClinicalTrials.gov